References

  • Ali AA, Avilés Elescano D, Grover DS. Bimatoprost SR for glaucoma therapy implanted at the slit-lamp in a real-world setting. Clin Ophthalmol. 2024;18:1371-1377.
  • Ayyala RS, Chaudhry AL, Okogbaa CB, Zurakowski D. Comparison of surgical outcomes between canaloplasty and trabeculectomy at 12 months’ follow-up. Ophthalmology. 2011;118:2427-2433.
  • Bacharach J, Tatham A, Ferguson G, et al; ARTEMIS 2 Study Group. Phase 3, randomized, 20-month study of the efficacy and safety of bimatoprost implant in patients with open-angle glaucoma and ocular hypertension (ARTEMIS 2). Drugs. 2021;81:2017-2033.
  • Belamkar A, Harris A, Zukerman R, et al. Sustained release glaucoma therapies: Novel modalities for overcoming key treatment barriers associated with topical medications. Ann Med. 2022;54:343-358.
  • Berdahl JP, Sarkisian SR Jr, Ang RE, et al; Travoprost Intraocular Implant Study Group. Efficacy and safety of the travoprost intraocular implant in reducing topical IOP-lowering medication burden in patients with open-angle glaucoma or ocular hypertension. Drugs. 2024;84:83-97.
  • Bowers ME, Wong MK, Ventimiglia J, et al. Effect of bimatoprost sustained-release intracameral implant on intraocular pressure and medication burden in patients with prior glaucoma surgery. J Fr Ophtalmol. 2024;47:103996.
  • Centers for Disease Control and Prevention (CDC). About Glaucoma. May 15, 2024. Accessed 2/26/26 2025. www.cdc.gov/vision-health/about-eye-disorders/glaucoma.html
  • Cheng CM, Rehmani C, Chin J. Prostaglandin intracameral implants for ocular hypertension and open-angle glaucoma. J Pharm Technol. 2025;41:144-150.
  • Cvenkel B, Kolko M. Devices and treatments to address low adherence in glaucoma patients: A narrative review. J Clin Med. 2022;12:151.
  • Gedde SJ, Vinod K, Bowden EC, et al. Special commentary: Reporting clinical endpoints in studies of minimally invasive glaucoma surgery. Ophthalmology. 2025;132:141-153.
  • Gedde SJ, Vinod K, Wright MM, et al; American Academy of Ophthalmology Preferred Practice Pattern Glaucoma Panel. Primary open-angle glaucoma preferred practice pattern. Ophthalmology. 2021;128(1):P71-P150.
  • Gedde SJ, Kolomeyer NN, Challa P, et al. on behalf of the American Academy of Ophthalmology Preferred Practice Pattern Glaucoma Committee. Primary open-angle glaucoma suspect preferred practice pattern. Ophthalmology. In press. 2/9/26. Accessed 2/10/26.www.aaojournal.org/article/S0161-6420(25)00814-0/abstract
  • Grover DS, Flynn WJ, Bashford KP, et al. Performance and safety of a new ab interno gelatin stent in refractory glaucoma at 12 months. Am J Ophthalmol. 2017;183:25-36.
  • Guedes RAP, Gravina DM, Guedes VMP, et al. Five-year outcomes of iStent inject implantation with or without phacoemulsification in eyes with open-angle glaucoma. Ophthalmol Ther. 2025;14:1219-1235.
  • Hunter L. How sustained-release is impacting glaucoma. January 10, 2025. Accessed 2/26/26. www.reviewofophthalmology.com/article/how-sustainedrelease-is-impacting-glaucoma
  • Imperato JS, Zou KH, Li JZ, Hassan TA. Clinical practice management of primary open-angle glaucoma in the United States: an analysis of real-world evidence. Patient Prefer Adherence. 2022;16:2213-2227.
  • Jain N, Fan Gaskin JC. Minimally Invasive Glaucoma Surgery: Is It Here to Stay? Clin Exp Ophthalmol. 2025;53(8):1025-1038.
  • Jampel HD, Musch DC, Gillespie BW, Lichter PR, Wright MM, Guire KE; Collaborative Initial Glaucoma Treatment Study Group. Perioperative complications of trabeculectomy in the collaborative initial glaucoma treatment study (CIGTS). Am J Ophthalmol. 2005;140:16-22.
  • Katz LJ, Myers JS, Herndon LW, et al. Interventional glaucoma: Improving the patient-provider educational exchange. Clin Ophthalmol. 2024;18:3365-3374.
  • Kolko M, Tatham AJ, Lim KS, et al; ATHENA STUDY GROUP. Phase 3, randomized, comparison study of intracameral bimatoprost implant 10 µg and selective laser trabeculoplasty. Am J Ophthalmol. 2025;272:19-37.
  • Mann E, Kammer JA, Sawhney G, et al. Prospective 18-month study of bimatoprost intracameral implant in patients with open-angle glaucoma or ocular hypertension in US clinical practice. Drugs. 2025;85:397-414.
  • Medeiros FA, Walters TR, Kolko M, et al; ARTEMIS 1 Study Group. Phase 3, randomized, 20-month study of bimatoprost implant in open-angle glaucoma and ocular hypertension (ARTEMIS 1). Ophthalmology. 2020;127:1627-1641.
  • Medeiros FA, Sheybani A, Shah MM, et al. Single administration of intracameral bimatoprost implant 10 µg in patients with open-angle glaucoma or ocular hypertension. Ophthalmol Ther. 2022;11:1517-1537.
  • Moore DE Jr, Green JS, Gallis HA. Achieving desired results and improved outcomes: integrating planning and assessment throughout learning activities. J Contin Educ Health Prof. 2009;29(1):1-15.
  • Morse AR, Seiple WH. Decreasing avoidable vision loss: Identifying antecedents of adherence. Clin Ophthalmol. 2020;14:3735-3739.
  • Musch DC, Gillespie BW, Lichter PR, et al. CIGTS study investigators. Visual field progression in the collaborative initial glaucoma treatment study: The impact of treatment and other baseline factors. Ophthalmology. 2009;116:200-207.
  • Newman-Casey PA, Niziol LM, Gillespie BW, et al. The association between medication adherence and visual field progression in the collaborative initial glaucoma treatment study. Ophthalmology. 2020;127:477e483.
  • Rhee DJ, Sancheti H, Rothman AL, et al. Primary practice patterns for the initial management of open angle glaucoma. J Glaucoma. 2024;33:671-678.
  • aSarkisian SR, Ang RE, Lee AM, et al. Travoprost intracameral implant for open-angle glaucoma or ocular hypertension: 12-month results of a randomized, double-masked trial. Ophthalmol Ther. 2024;13:995-1014.
  • bSarkisian SR Jr, Mitchell EC. Real-world analysis of the efficacy of bimatoprost sustained-release glaucoma implant where American Indians comprise the largest minority population. Clin Ophthalmol. 2024;18:917-927.
  • Sheybani A, Vera V, Grover DS, et al. Gel stent versus trabeculectomy: The randomized, multicenter, Gold-Standard Pathway Study (GPS) of effectiveness and safety at 12 months. Am J Ophthalmol. 2023;252:306-325.
  • Silverstein SM, Oddone F, Kolko M, et al; TRITON Study Group. Safety and longevity of intraocular pressure control after bimatoprost implant administration: Interim analysis of a phase 3b clinical trial (TRITON). Drugs. 2025;85:557-570.
  • Stuart A. Bimatoprost implant: What role will it play in glaucoma management? December 1, 2020. Accessed 2/26/26. www.aao.org/eyenet/article/bimatoprost-implant-glaucoma-management
  • Torbey J, Paillard A, Rao HL, et al. XEN 45 gel stent implantation in open angle glaucoma: 5-year results of a prospective study. J Glaucoma. 2023;32:909-917.
  • Traverso CE, Carassa RG, Fea AM, et al. Effectiveness and safety of Xen gel stent in glaucoma surgery: A systematic review of the literature. J Clin Med. 2023;12:5339.
  • Wong MK, Bowers ME, Ventimiglia J, et al. Short-term outcomes of bimatoprost sustained-release intracameral implant in glaucoma. J Glaucoma. 2023;32:738-743.
  • Yang SA, Ciociola EC, Mitchell W, et al; IRIS Registry Analytic Center Consortium. Effectiveness of microinvasive glaucoma surgery in the United States: Intelligent Research in Sight Registry Analysis 2013-2019. Ophthalmology. 2023;130:242-255.
Return to Resources



















American Academy of Ophthalmology and Paradigm Medical Communications, LLC present this resource for educational purposes only. Healthcare professionals are expected to employ their own knowledge and judgement during any discussion with, or treatment of, their patients.

For questions or technical support please email us at contactus@paradigmmc.com.

This initiative is provided by the American Academy of Ophthalmology, with support from Paradigm Medical Communications, LLC.

This initiative is supported by an independent medical education grant from AbbVie, Inc.

© American Academy of Ophthalmology